Plasma net cholesteryl ester (CE) transfer and optimum cholesteryl ester transfer protein (CETP) activity were determined in primary hypertriglyceridemic (a = 11) and normolipidemic (a = 15) individuals. The hypertriglyceridemic group demonstrated threefold greater net CE transfer leading to enhanced accumulation of CE in VLDL. This increased net transfer was not accompanied by a change in CETP activity. In normolipidemia, but not in hypertriglyceridemia, net CE transfer correlated with VLDL triglyceride (r = 0.92, P < 0.001). In contrast, net CE transfer in hypertriglyceridemia, but not in normolipidemia, correlated with CETP activity (r = 0.73, P < 0.01). Correction of hypertriglyceridemia with bezafibrate reduced net CE transfer towards normal and restored the correlation with VLDL triglyceride (r = 0.90, P < 0.005) while suppressing the correlation with CETP activity. That net CE transfer depends on VLDL concentration was confirmed by an increase ofnet CE transfer in normolipidemic plasma supplemented with purified VLDL. Supplementation of purified CETP to normolipidemic plasma did not stimulate net CE transfer. In contrast, net CE transfer was enhanced by addition of CETP to both plasma supplemented with VLDL and hypertriglyceridemic plasma. 
1. Abbreviations used in this paper: CE, cholesteryl ester, CETP, CE transfer protein; E600, di-ethyl 4-nitrophenyl phosphate; LCAT, lecithin-cholesterol acyltransferase; Tg, triglyceride.
teins by cholesteryl ester transfer protein (CETP) (1, 2 ; see ref. 3 for review). Kinetic data (4) and in vitro studies (5) indicate that transfer of HDL CE, derived from the lecithin-cholesterol acyltransferase (LCAT) reaction, to lower density, apo B-containing lipoproteins is an important route for clearance ofHDL CE. However, the absence of premature atherosclerosis in subjects with markedly increased HDL levels caused by CETP deficiency (null phenotype) (6, 7) suggests that the action of CETP could promote atherogenesis. Low plasma HDL concentration, which is an important predictor of coronary heart disease risk (8) (9) (10) , is commonly observed in hypertriglyceridemic subjects. Since HDL cholesterol concentration is inversely related to plasma Tg levels (1 1, 12) , the low HDL cholesterol levels in hypertriglyceridemia could result from an increased rate of CE transfer from HDL to Tg-rich lipoproteins.
Consistent with this analysis, previous studies have shown that compared to normal, hypertriglyceridemic HDL are CE depleted and Tg enriched, while VLDL are enriched with CE (13) . In contrast, plasma incubation studies have shown that in hypertriglyceridemic subjects with vascular disease, the rate of net CE transfer from HDL to apo B-containing lipoproteins is reduced (5) . This observation suggests that the apoB-containing lipoproteins of these subjects display impaired ability to accept CE from HDL (5, 14) . Recent investigations, however, have shown that apo B-containing lipoproteins of hypertriglyceridemic subjects accept HDL CE at a rate comparable with normal subjects (15) . Also, net CE transfer has been reported to be enhanced in other conditions ofhypertriglyceridemia, i.e., dysbetalipoproteinemia (16), and postprandial lipemia (17, 18) . To address this controversial issue, we investigated the mechanism of CETP-mediated transfer of CE in a homogeneous group of subjects with primary hypertriglyceridemia, and in a control group of normolipidemic subjects matched for age and sex.
In this paper, we report that in primary hypertriglyceridemia, the rate of CE accumulation in VLDL is increased threefold compared to normolipidemia. This enhanced net CE transfer does not result from a change in optimum CETP activity, but rather from an increase in VLDL concentration.
Subjects. This study involved the participation of informed, consenting adult human subjects. Hypertriglyceridemic patients (VLDL Tg > 1.5 mmol/liter or 130 mg/dl) attending Leeds General Infirmary Lipid Clinic, Leeds, England, were screened for secondary causes of hyperlipidemia. Subjects with glucose intolerance, liver or kidney disease, thyroid dysfunction, or alcoholism were excluded. To ensure a homogeneous population, those individuals with raised LDL (1.006 < d < 1.063 g/ml) cholesterol concentration (> 4.2 mmol/liter or 160 mg/dl) were also excluded from the study. Of the I1 selected hypertriglyceridemic subjects, none had taken lipid-active medication in the previous four months, and each was following lipid clinic dietary guidance. 8 of these 11 subjects, diagnosed with (n = 4) or having family history of (n = 4) cardiovascular disease, were restudied after 6 wk treatment with bezafibrate (200 mg, three times per day). The criterion for positive family history was diagnosis of cardiovascular disease in first or second degree relatives: one before age 50, two before age 60, or three before age 65. 15 normolipidemic control subjects (LDL cholesterol . 4.2 mmol/liter, and VLDL Tg . 1.2 mmol/liter or 110 mg/dl) were matched for age and sex.
Sample preparation. After an overnight fast, blood was collected into tubes containing disodium EDTA (final concentration, 1 mg/ml) at 4VC. Aprotinin (0.14 IU/ml) and E600 (di-ethyl 4-nitrophenyl phosphate) (2 mM, final concentration) were added to all plasma samples to inhibit protease and LCAT activities, respectively.
Measurement oflipids and apoproteins. Concentrations of plasma and lipoprotein total cholesterol, unesterified cholesterol, and triglyceride were measured using enzymatic reagents, and are expressed as millimoles per liter using molecular weights of 387 for cholesterol and 885 for triglyceride. CE was calculated as the difference between measured total and unesterified cholesterol concentrations. HDL total and unesterified cholesterol were determined in plasma after precipitation of apo B-containing lipoproteins with sodium heparin (250 U/ml plasma) and MnCl2 (92 mM, final concentration) at 4°C (19) . To prevent interference of excess manganese ions with these lipid determinations, the enzymatic reagents were first supplemented with 8 mM EDTA. Concentrations of apoproteins Al and B in plasma were determined by immunoturbidimetric methods. Protein was determined by the method of Lowry et al. (20) using BSA as standard.
Isolation of lipoprotein fractions. VLDL and LDL were obtained from individual plasma samples (1-1.5 ml) by sequential ultracentrifugation. VLDL (d < 1.006 g/ml) was isolated using a rotor (TFT1 80.4; Sorvall Instruments Div., part ofDuPont Co., Newton, CT) at 310,000 g for 4 h 10 min at4C. LDL (1.006 < d < 1.063 g/ml) was isolated by a second centrifugation at 265,000 g for 7 Purification ofCETP. Human plasma CETP was purified 500-fold from blood bank plasma (800 ml). Plasma (d = 1.21 g/ml) was centri- were precipitated using heparin and MnCl2. CETP activity was determined from the loss of 3H-CE from the HDL supernatant, minus the loss from blank samples incubated for the same time without plasma or purified CETP. Points are expressed as mean±SD of quadruplicate determinations.
mM Tris, 150 mM NaCl, 2 mM EDTA, pH 7.4, was aliquoted and stored at -70°C. No LCAT activity (22) was detectable in this fraction.
Statistical analyses. Statistical significance of the differences between two means was determined by two-tailed Student's t test for paired or unpaired samples as indicated. Correlations were analyzed using linear Pearson correlation coefficient.
Results
Increased net CE transfer in hypertriglyceridemic subjects does not result from changes in CETP activity. Compared to the normolipidemic group, hypertriglyceridemic subjects showed significantly higher VLDL Tg and significantly lower HDL cholesterol (Table I) . Two parameters were determined to assess neutral lipid redistribution between lipoprotein subfractions. Net CE transfer was measured as the change of CE concentration in VLDL and LDL fractions following whole plasma incubations. Plasma optimum CETP activity was measured under conditions that minimize the relative effects of donor and acceptor lipoproteins. The latter parameter provides a measure of CETP mass (23) . In the hypertriglyceridemic group, net CE transfer was enhanced compared to normolipidemic subjects leading to a threefold increased accumulation of CE in VLDL (Table I) . Net CE transfer to LDL was not significantly increased in hypertriglyceridemia. For both normolipidemic and hypertriglyceridemic subjects, net CE transfer to VLDL was accompanied by an equivalent molar net Tg transfer from VLDL (data not shown). There was no statistically significant increase in optimum CETP activity in hypertriglyceridemic plasma. These data suggested that net transfer of neutral lipids is accelerated in hypertriglyceridemia, but does not result from an increase in plasma CETP mass. Net CE transfer correlates with plasma VLDL triglyceride concentration only in the normolipidemic group. The observation that CETP activity is normal in hypertriglyceridemia led us to question the ability of lipoprotein neutral lipid levels to modulate the rate of net CE transfer. Since net CE transfer to LDL was small, and not statistically different between the two groups studied, we analyzed potential relationships of net CE transfer with lipoprotein CE donor (HDL) and acceptor (VLDL) concentrations. A positive linear correlation (r = 0.92, P < 0.001) between net CE transfer and VLDL Tg was found in the normolipidemic group (Fig. 3 A) but not in the hypertriglyceridemic group (Fig. 3 B) . The correlation observed in normolipidemic subjects is consistent with data reported previously in 15 other normolipidemic controls (24) . No statistically significant correlation could be found in either group, between net CE transfer and HDL CE concentration (Fig. 3, C and D) .
These results suggested that in normolipidemia, the concentration of CE acceptor (VLDL), rather than CE donor (HDL), determines the rate of net CE transfer. For the hypertriglyceridemic group, however, the absence of significant correlations between net CE transfer and either acceptor or donor lipoprotein lipid concentrations indicated that the rate of net CE transfer is independent of plasma lipid levels in these subjects.
Net CE transfer correlates with CETP activity only in the hypertriglyceridemic group. We next questioned whether in hypertriglyceridemia the rate of net CE transfer is related to CETP mass. Fig. 4 shows that, in contrast with the normolipidemic group (Fig. 4 A) , the hypertriglyceridemic group (Fig. 4 B) displayed a positive significant correlation between net CE transfer and optimum CETP activity. Taken together, these observations led us to hypothesize that: (a) the rate of net CE transfer in normolipidemia is limited by Tg-rich acceptor-lipoprotein concentration; and (b) in hypertriglyceridemia, enhanced net CE transfer as a result of raised VLDL concentration, is limited by the normal CETP mass in these subjects.
Supplementation of normolipidemic plasma with normal VLDL increases net CE transfer. To test whether net CE transfer is determined by VLDL concentration, we created conditions of hypertriglyceridemia in vitro by supplementing HYPERTRIGLYCERIDELIA plemented with CETP. Consistent with that observed in VLDL-enriched plasma (Fig. 6) , CETP supplementation ofhypertriglyceridemic plasma further increased the initially high 500 B rate of net CE transfer (Table II) Effect on net CE transfer ofsupplementing normolipidemic plasma with purified normal HDL or LDL. To define the roles ofHDL and LDL in determining the rate ofnet CE transfer, we supplemented plasma with increasing concentrations of these 0 2.0 4.0 lipoproteins isolated from the same subject (Fig. 7) . Fig. 7 Fig. 5 shows were significantly reduced and HDL cholesterol was signifiofVLDL concentration.
cantly increased (Table III) . Net CE transfer was reduced to ge (i.e., < 1.2 mmol/liter half the pretreatment level as a consequence of significantly ised with VLDL Tg conless accumulation of CE in the VLDL fraction (Table III) Fig. 6 shows that addition of CETP enhanced net CE transfer in VLDL-enriched plasma, but not in normolipidemic plasma. The inset ofFig. 6 demonstrates that the optimum CETP activities in both VLDL-rich and normal plasma increased linearly with the addition of CETP. Thus, the inability of CETP to increase net CE transfer in normal plasma is consistent with this protein being in excess in normolipidemic subjects.
To further test the hypothesis that CETP is rate limiting in hypertriglyceridemia, hypertriglyceridemic plasma were sup- in the eight subjects before and after treatment. The significances ofthese correlations before treatment were not different from those observed in the 11 original subjects (Figs. 3 and 4) . Fig. 8 shows the correlations after bezafibrate treatment. The correlation between net CE transfer and optimum CETP activity did not reach statistical significance (Fig. 8 A) , contrasting with the significant correlation observed prior to treatment. Concomitantly, a statistically significant correlation between net CE transfer and plasma VLDL Tg concentration was observed after bezafibrate treatment (Fig. 8 B) . The lack of correlation between net CE transfer and HDL CE observed before bezafibrate, persisted after therapy (Fig. 8 C) . This showed that correction of hypertriglyceridemia with bezafibrate suppresses the relationship of net CE transfer with CETP activity, and restores the relationship with plasma VLDL Tg. These data therefore further support the hypothesis that Tg-rich lipoprotein concentration determines the rate of net CE transfer in normolipidemia, while CETP limits net CE transfer in the presence of high VLDL concentrations.
Discussion
The data presented here show that in plasma from primary hypertriglyceridemic subjects, net CE transfer to VLDL is CETP added pg Figure 6 . Effect on net CE transfer of CETP supplementation to plasma enriched (m) or not (e) with normal VLDL. Using the same subjects as in Fig. 5 , fasting 1-ml plasma aliquots from subject 2 were enriched or not with VLDL from subject 1, then supplemented or not (first point) with increasing concentrations of purified (500-fold) CETP in a final vol of 1.4 ml. These samples were incubated at 37°C for either 4 h (normolipidemic plasma) or 2 h (VLDL-enriched plasma). All samples contained LCAT inhibitor ( The possibility that VLDL concentration limits net CE transfer in normolipidemia was verified by the observation that supplementation of plasma with purified VLDL increased net CE transfer. Conversely, the hypothesis that CETP is rate limiting in hypertriglyceridemia was verified by supplementation of (13, 26) could modulate the ability of such particles to accumulate CE (27) . support. Thanks are extended to Drs. Jean Davignon, Ira Goldberg, and Alfredo Lopez for providing the plasma from subjects presented in Table II . We also wish to thank Dr. Charles Sloop for his assistance in preparation of the figures. 
